CLEARMIND MEDICINE INC. (Unaudited) Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) Alan Rootenberg, Director, CFO Adi Zuloff-Shani, Director, CEO F-2 Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Expressed in United States Dollars) (Unaudited) On November 14, 2022, the Company completed a public offering for aggregate gross proceeds of US$7.5 million and up listing to the Nasdaq Capital Market ("Nasdaq"), see ...

c. Significant Accounting Estimates and Judgments (continued) Significant Judgments 3. Short-term Investment CLEARMIND MEDICINE INC. Notes to the Condensed Interim Consolidated Financial Statements (Expressed in Canadian Dollars) (Unaudited) a. Compensation to key management personnel | --- | --- | --- | |---------------------------------|-------|-------| | | | | | Amounts owed to officers | | | | | | | | Amounts owed to directors | | | CLEARMIND MEDICINE INC. (iii) During the three months ended January 31, ...

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Emerging Growth Company ☒ If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ †The term "new or revised financial accounting standard" refers to any update issued by ...